High-Tech Imaging Helps Unravel Hepatitis C's Secrets
XE-Bio From Park Systems Brings Promise in Fight Against Hepatitis C
February 16, 2010
(Nanowerk News) The fight against the liver disease hepatitis C has been something of an impasse for years, with more than 150 million people currently infected, and traditional antiviral treatments causing nasty side effects and often falling short of a cure. Park Systems’ XE-Bio helped researchers at Stanford University discover a vulnerable step in the virus’ reproduction process that in lab testing could be effectively targeted with an obsolete antihistamine. XE-Bio successfully imaged and analyzed two of the compounds that most potently inhibit vesicle aggregation revealed their mechanism of action on 4BAH2 function. These results provide new insight into the molecular mechanism of HCV replication platform assembly, and demonstrate the utility of a novel small-molecule anti-HCV strategy.
Continue reading this entire article: